Will EU scrutiny procedure for high-risk devices rival US FDA processes for costs and delays?
This article was originally published in Clinica
Executive Summary
The European Commission’s anticipated proposal for the review of high-risk and innovative devices may result in the implementation of policies similar to the FDA’s premarket authorisation process.